Phase 1 Multiple Sclerosis Trial, Recruiting NCT05451251 Sponsor: Université de Sherbrooke Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Phase 1 Multiple Sclerosis Trial, Recruiting

NCT05451251
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be an adult aged 18 or older
  • You must have trigeminal neuralgia (a severe facial nerve pain condition) that has not responded to at least 3 different medications AND at least two surgical procedures aimed at reducing nerve activity (such as radiosurgery or certain types of nerve surgery)
  • You must have a specific lesion (an area of abnormal tissue) in a part of the brain called the pons, which has been confirmed by an MRI scan and shown to be touching the trigeminal nerve pathway

Who may not be able to join:

  • You cannot safely have an MRI scan for any reason (confirm with trial site)
  • You have a health condition that means the trial procedure would not be medically safe for you (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 819-346-1110

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Université de Sherbrooke
Registry
ClinicalTrials.gov
Start date
15 October 2024
Est. completion
15 October 2025

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Demonstrating the feasibility of the intervention by assessing protocol completion without deviation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov